WHO ELSE BENEFITS FROM THE NEW PROCESS?
Benefits are universal. There are no perceivable losers and no compromising of professional independence. Rather it is enhanced and can be seen to be so by its very overtness, transparency and full accountability.The Patient is the most important beneficiary. The patients diagnosis, management and drug treatment are all assisted and enhanced by the new process. The patients doctor now has access to a plethora of very useful desktop management and therapeutics tools and more importantly has prescribing independence restored. The funds generated by Cost Recovery or Compensation all go back directly or indirectly into patient services.The Doctor who cares for that patient who not only needs the correct drug data but requires the environment which is conducive to purposeful detailing. This must necessarily include some source of funding for infrastructure and impact analysis reporting. That funding in turn is redirected to academic or patient-care initiatives.The Pharma Company, big or sma
